X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (3407) 3407
humans (3089) 3089
oncology (2134) 2134
male (1689) 1689
female (1568) 1568
middle aged (1442) 1442
aged (1420) 1420
hematology (1277) 1277
chemotherapy (1218) 1218
adult (1114) 1114
antineoplastic combined chemotherapy protocols - therapeutic use (1091) 1091
multiple myeloma (1020) 1020
treatment outcome (1011) 1011
multiple myeloma - drug therapy (835) 835
cancer (807) 807
bortezomib (754) 754
stem-cell transplantation (749) 749
plus dexamethasone (720) 720
care and treatment (670) 670
therapy (620) 620
antineoplastic agents - therapeutic use (570) 570
antineoplastic combined chemotherapy protocols - adverse effects (548) 548
dexamethasone (533) 533
thalidomide (533) 533
pharmacology & pharmacy (529) 529
lenalidomide plus dexamethasone (523) 523
aged, 80 and over (522) 522
lenalidomide (498) 498
survival (469) 469
thalidomide - analogs & derivatives (469) 469
trial (459) 459
medicine & public health (454) 454
drug therapy (421) 421
research (416) 416
disease-free survival (407) 407
prognosis (399) 399
animals (394) 394
dexamethasone - administration & dosage (388) 388
hematology, oncology and palliative medicine (383) 383
transplantation (383) 383
antineoplastic agents - adverse effects (380) 380
elderly-patients (364) 364
multiple myeloma - therapy (355) 355
thalidomide - administration & dosage (352) 352
combination (332) 332
antineoplastic combined chemotherapy protocols - administration & dosage (328) 328
clinical trials (328) 328
retrospective studies (323) 323
docetaxel (317) 317
double-blind (316) 316
analysis (313) 313
thalidomide - therapeutic use (304) 304
survival analysis (295) 295
survival rate (293) 293
cisplatin (290) 290
phase-ii trial (287) 287
health aspects (279) 279
multiple myeloma - mortality (274) 274
drug administration schedule (267) 267
recurrence (259) 259
stem cells (259) 259
neoplasm staging (256) 256
abridged index medicus (254) 254
clinical trials as topic (248) 248
risk factors (247) 247
non-hodgkins-lymphoma (246) 246
randomized-trial (244) 244
drug therapy, combination (234) 234
phase-ii (233) 233
transplantation, autologous (233) 233
multiple myeloma - pathology (232) 232
combination therapy (229) 229
thalidomide - adverse effects (226) 226
antineoplastic agents (218) 218
open-label (217) 217
antineoplastic agents - administration & dosage (214) 214
thalidomide plus dexamethasone (213) 213
combined modality therapy (209) 209
dosage and administration (208) 208
cyclophosphamide (206) 206
dose-response relationship, drug (203) 203
follow-up studies (203) 203
metastasis (202) 202
dexamethasone - therapeutic use (201) 201
antimitotic agents (199) 199
patients (199) 199
randomized controlled-trial (199) 199
stem cell transplantation (198) 198
prednisone (197) 197
vomiting - chemically induced (197) 197
lung neoplasms - drug therapy (196) 196
lymphomas (196) 196
patient outcomes (194) 194
multiple myeloma - diagnosis (190) 190
taxoids - administration & dosage (190) 190
antiemetics - therapeutic use (187) 187
disease progression (187) 187
boronic acids - administration & dosage (186) 186
pyrazines - administration & dosage (185) 185
melphalan (184) 184
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3925) 3925
German (21) 21
French (20) 20
Spanish (12) 12
Russian (3) 3
Italian (2) 2
Japanese (2) 2
Korean (2) 2
Polish (2) 2
Chinese (1) 1
Hungarian (1) 1
Lithuanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer, ISSN 0008-543X, 02/2006, Volume 106, Issue 4, pp. 848 - 858
BACKGROUND. Pegylated liposomal doxorubicin has pharmacologic and safety advantages over conventional doxorubicin. METHODS. For this noninteriority trial, 192... 
Dexamethasone | Neutropenic fever | Drug toxicity | Multiple myeloma | Liposomes | Drug resistance | Doxorubicin | Pegylated liposomal doxorubicin | Vincristine | Neoplasms | dexamethasone | 1ST-LINE TREATMENT | multiple myeloma | vincristine | ONCOLOGY-GROUP | liposomes | COMBINATION THERAPY | neutropenic fever | CONVENTIONAL DOXORUBICIN | TRANSPLANTATION | pegylated liposomal doxorubicin | THALIDOMIDE PLUS DEXAMETHASONE | KAPOSIS-SARCOMA | ONCOLOGY | drug toxicity | REDUCED-DOSE DEXAMETHASONE | VAD | doxorubicin | drug resistance | neoplasms | DVD-T | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Polyethylene Glycols - adverse effects | Male | Fever - chemically induced | Multiple Myeloma - drug therapy | Doxorubicin - analogs & derivatives | Aged, 80 and over | Vincristine - administration & dosage | Adult | Female | Neutropenia - chemically induced | Doxorubicin - administration & dosage | Dexamethasone - administration & dosage | Administration, Oral | Catheterization, Central Venous | Treatment Outcome | Polyethylene Glycols - administration & dosage | Multiple Myeloma - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Infusions, Intravenous | Doxorubicin - adverse effects | Pharmaceutical research | Drugs | Myelocytic leukemia | Reports | Nonlymphoid leukemia | Research | Drug therapy, Combination | Drug therapy | Health aspects | Index Medicus | Abridged Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 389, Issue 10068, pp. 519 - 527
Journal Article
Blood, ISSN 0006-4971, 07/2012, Volume 120, Issue 1, pp. 9 - 19
Journal Article
British Journal of Haematology, ISSN 0007-1048, 09/2014, Volume 166, Issue 5, pp. 702 - 710
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2017, Volume 376, Issue 14, pp. 1311 - 1320
In this trial, 700 patients with myeloma were randomly assigned to receive RVD therapy (lenalidomide, bortezomib, and dexamethasone) with or without autologous... 
DIAGNOSED MULTIPLE-MYELOMA | MEDICINE, GENERAL & INTERNAL | PHASE-III | AUTOLOGOUS TRANSPLANTATION | DARATUMUMAB MONOTHERAPY | INITIAL TREATMENT | FOLLOW-UP | PREDNISONE PLUS THALIDOMIDE | RANDOMIZED CONTROLLED-TRIAL | STEM-CELL TRANSPLANTATION | ELDERLY-PATIENTS | Humans | Middle Aged | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Induction Chemotherapy | Male | Transplantation, Autologous | Stem Cell Transplantation | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Adult | Female | Maintenance Chemotherapy | Thalidomide - adverse effects | Dexamethasone - administration & dosage | Lenalidomide | Kaplan-Meier Estimate | Combined Modality Therapy | Thalidomide - administration & dosage | Disease-Free Survival | Bortezomib - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Bortezomib - adverse effects | Aged | Usage | Care and treatment | Bortezomib | Dexamethasone | Patient outcomes | Multiple myeloma | Transplantation of organs, tissues, etc | Dosage and administration | Autografts | Gastrointestinal tract diseases | Minimal residual disease | Stem cell transplantation | Peripheral neuropathy | Patients | Chemotherapy | Melphalan | Thromboembolism | Neutropenia | Index Medicus | Abridged Index Medicus | Life Sciences | Cancer
Journal Article
Leukemia, ISSN 0887-6924, 08/2015, Volume 29, Issue 8, pp. 1721 - 1729
Journal Article
Journal Article
Leukemia, ISSN 0887-6924, 06/2017, Volume 31, Issue 6, pp. 1368 - 1374
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2012, Volume 30, Issue 20, pp. 2475 - 2482
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 2, pp. 142 - 152
Journal Article